Micro/nanomachines: What is needed for them to become a real force in cancer therapy?

Lucie Reinišová, Soňa Hermanová, Martin Pumera

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.

Original languageEnglish
Pages (from-to)6519-6532
Number of pages14
JournalNanoscale
Volume11
Issue number14
DOIs
Publication statusPublished - 2019 Apr 14

Fingerprint

Poisons
Medical applications
Drug Delivery Systems

All Science Journal Classification (ASJC) codes

  • Materials Science(all)

Cite this

Reinišová, Lucie ; Hermanová, Soňa ; Pumera, Martin. / Micro/nanomachines : What is needed for them to become a real force in cancer therapy?. In: Nanoscale. 2019 ; Vol. 11, No. 14. pp. 6519-6532.
@article{56e80ed409fd4dce93c047da5b6d27bc,
title = "Micro/nanomachines: What is needed for them to become a real force in cancer therapy?",
abstract = "Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.",
author = "Lucie Reinišov{\'a} and Soňa Hermanov{\'a} and Martin Pumera",
year = "2019",
month = "4",
day = "14",
doi = "10.1039/c8nr08022d",
language = "English",
volume = "11",
pages = "6519--6532",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "14",

}

Micro/nanomachines : What is needed for them to become a real force in cancer therapy? / Reinišová, Lucie; Hermanová, Soňa; Pumera, Martin.

In: Nanoscale, Vol. 11, No. 14, 14.04.2019, p. 6519-6532.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Micro/nanomachines

T2 - What is needed for them to become a real force in cancer therapy?

AU - Reinišová, Lucie

AU - Hermanová, Soňa

AU - Pumera, Martin

PY - 2019/4/14

Y1 - 2019/4/14

N2 - Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.

AB - Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85064129502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064129502&partnerID=8YFLogxK

U2 - 10.1039/c8nr08022d

DO - 10.1039/c8nr08022d

M3 - Review article

C2 - 30632584

AN - SCOPUS:85064129502

VL - 11

SP - 6519

EP - 6532

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 14

ER -